Tagged with GI

Hong Kong Former Hong Kong SAR Chief Executive CY Leung  discusses Hong Kong’s unique positioning within the Greater Bay Area and the importance of its openness, international business mindset, and strong sense of social responsibility in maintaining its global relevance. Leung also reflects on Hong Kong’s response to political and economic uncertainties…

Saudi Arabia Dr Mahmoud Alyamani, Health & Well-Being Sector Head at NEOM, the sustainable region taking shape in northwest Saudi Arabia. He discusses NEOM’s innovative healthcare vision, emphasizing a proactive, data-driven approach using digital twins and AI. He also highlights the importance of global partnerships to co-create advanced health solutions and NEOM’s…

Global In 2024, people living with HIV have more, and more varied, access to HIV prevention and treatment options than ever before. Thanks to global activism efforts forcing pharma to step up, and the establishment of some vital institutional structures in the first decade of the millennium, access is up, while…

Mexico This year has seen no less than five GM changes at international pharma companies’ Mexican affiliates. Pfizer, MSD, Roche, Sanofi and Gilead have all taken on new local leadership. In some cases, the appointments represent a first for affiliates that have never had female leaders while in others they coincide…

Mexico Drawing on an industry track record of over 25 years, Fernando Fogarin has recently become the strategic project lead for emerging markets at women’s health specialist Organon. He shares his priorities and the particularities of the Mexican market, discussing the positive impact of the country’s upcoming biosimilars reform; Organon’s efforts…

China A roundup of some of the biggest pharma industry news from China, including Fosun’s bid for Henlius Biotech; the revision of the US’s Biosecure Act to provide more time for cutting ties with China; Baili Tianheng’s second Hong Kong listing; Hasten’s acquisition of asset rights for 14  products from Celltrion,…

Saudi Arabia As life expectancy increases, how do we ensure that quality of life does too? That is the conundrum that Saudi Arabia’s Hevolution Foundation was set up to help solve. Hevolution invests in extending the healthy human lifespan across the world through research and treatments which target age-related diseases and conditions.…

Saudi Arabia As a part of the sweeping transformation Saudi Arabia is achieving thanks to its Vision 2030, the Kingdom is also advancing its research ambitions. With the restructuring of its regulatory framework along with its well-established network of research institutes and bolstered by the integration of electronic health records, Saudi has…

Saudi Arabia Dr Eid Mansour, general manager of Gilead’s new Saudi affiliate, shares the strategic goals behind the creation of a strong direct presence in a region previously managed almost entirely through distributors and how these goals align with the kingdom’s Vision 2030 and the National Transformation Programme. He also outlines the…

China Since first establishing an affiliate in China back in 2017, Gilead Sciences has been able to introduce 11 innovative medicines to the Chinese market – eight of which have been included in the National Reimbursement Drug List – across HIV prevention & treatment, viral hepatitis, invasive fungal disease, and cancer.…

China Jimmy Wei founded Chime Biologics over 12 years ago with the vision of establishing a global biologics company in China, focusing on biosimilar development and CDMO services. The company’s growth since then has been influenced by the success of other biologics companies like WuXi Biologics and Samsung Biologics, regulatory changes…

Middle East & Africa Roula Youssef Halabi, SVP Global Fertility Services, discusses her six-year journey at CooperSurgical, establishing a footprint in the Middle East, overcoming cultural biases as a female executive and the shift that has led GCC countries to increasingly recognize the importance of women’s health. She also speaks about the need for…